Inhibitor Therapeutics, Inc. — Net Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d2779dd0-049c-4395-950b-45f5a852a596/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-3.3M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-012751 |
| FY 2024 | $-3.3M | 2024-01-01 – 2024-12-31 | evidence 0001641172-25-001190 |
| FY 2023 | $-3.0M | 2023-01-01 – 2023-12-31 | evidence 0001493152-24-011973 |
| FY 2022 | $12.1M | 2022-01-01 – 2022-12-31 | evidence 0001493152-23-010383 |
| FY 2021 | $-298.6k | 2021-01-01 – 2021-12-31 | evidence 0001193125-22-088832 |
| FY 2020 | $-1.1M | 2020-01-01 – 2020-12-31 | evidence 0001193125-21-095516 |
| FY 2019 | $-2.7M | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-090201 |
| FY 2018 | $-4.6M | 2018-01-01 – 2018-12-31 | evidence 0001193125-19-066503 |
| FY 2017 | $-5.1M | 2017-01-01 – 2017-12-31 | evidence 0001193125-18-047834 |
| FY 2016 | $-7.0M | 2016-01-01 – 2016-12-31 | evidence 0001193125-17-048025 |
| FY 2015 | $-3.9M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-446037 |
| FY 2014 | $-4.0M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-050220 |
| FY 2013 | $-1.8M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-144186 |
| FY 2012 | $186.4k | 2012-01-01 – 2012-12-31 | evidence 0001193125-14-144186 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Inhibitor Therapeutics, Inc. — all facts · Revenue · Operating Income